STOCK TITAN
  1. Home
  2. News
  3. BTAI

BioXcel Therapeutics Inc - BTAI STOCK NEWS

Welcome to our dedicated news page for BioXcel Therapeutics (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on BioXcel Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioXcel Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioXcel Therapeutics's position in the market.

News
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
Rhea-AI Summary
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) will report its first quarter 2024 financial results on May 9, 2024. The company, a biopharmaceutical utilizing AI in neuroscience and immuno-oncology, will host a conference call and webcast to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences earnings
-
News
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Rhea-AI Summary
BioXcel Therapeutics announces that a late-breaking abstract on preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeting. The trial, led by Georgetown University’s Lombardi Comprehensive Cancer Center, aims to evaluate the combination's efficacy in previously treated patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.75%
Tags
clinical trial
-
News
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Rhea-AI Summary
BioXcel Therapeutics plans to initiate the SERENITY At-Home Phase 3 trial to evaluate BXCL501 for the treatment of agitation in bipolar disorders or schizophrenia in a home setting. The trial will use a 120 mcg dose based on FDA feedback, aiming to expand the drug's label for outpatient use. The study will enroll approximately 200 patients and include additional efficacy evaluations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
News
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
Rhea-AI Summary
BioXcel Therapeutics, Inc. announces a registered direct offering of common stock and warrants, raising approximately $25 million. The offering includes 3,054,609 shares of common stock and accompanying warrants, as well as pre-funded warrants to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
offering
-
News
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
Rhea-AI Summary
BioXcel Therapeutics, Inc. (BTAI) secures European Patent for BXCL501 to treat agitation in individuals with dementia, expanding its intellectual property portfolio and commercialization potential globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
-
News
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Rhea-AI Summary
BioXcel Therapeutics, Inc. provides updates on late-stage clinical programs for BXCL501, focusing on treating agitation associated with Alzheimer’s dementia, bipolar disorders, and schizophrenia. The company plans to expand data for TRANQUILITY and SERENITY programs, emphasizing safety and efficacy. Financially, the company reported increased net revenue from IGALMI, reduced R&D and SG&A expenses, and a net loss for the fourth quarter and full year 2023. The company's cash and cash equivalents are estimated to fund operations through mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
earnings
News
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Rhea-AI Summary
BioXcel Therapeutics, Inc. (BTAI) will release its Q4 and full year 2023 financial results on March 12, 2024. The company uses AI for neuroscience and immuno-oncology drugs. A conference call and webcast will discuss the results and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
-
News
BioXcel Therapeutics Announces Termination of Proposed Public Offering
Rhea-AI Summary
BioXcel Therapeutics, Inc. terminates a $60.0 million public offering due to unfavorable market conditions. The company shifts focus to FDA meeting for Phase 3 trial of BXCL501 in treating agitation associated with dementia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.15%
Tags
offering
-
News
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Rhea-AI Summary
BioXcel Therapeutics, Inc. receives FDA Fast Track designation for BXCL701 in combination with a checkpoint inhibitor for treating metastatic small cell neuroendocrine prostate cancer. The company plans to discuss the registration path with the FDA, highlighting the potential of BXCL701 in addressing unmet medical needs in SCNC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
clinical trial
News
BioXcel Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
BioXcel Therapeutics, Inc. has announced an underwritten public offering of $60.0 million of shares of its common stock, with an option to purchase additional shares. The net proceeds will be used to fund ongoing and planned clinical trials, commercialization, and general corporate purposes. The offering is being made pursuant to a shelf registration statement on Form S-3 filed with the SEC. BofA Securities and Truist Securities are acting as joint book-running managers for the proposed public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.73%
Tags
offering
Stock BTAI logo
BioXcel Therapeutics Inc

Nasdaq:BTAI

BTAI Rankings

#4440 Ranked by Market Cap
#5252 Ranked by Stock Gains
N/A Ranked by Dividends

BTAI Stock Data

81.95M
21.69M
27.01%
28.51%
8.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New Haven

About BTAI

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.